Video
Dr. Finn on Current and Emerging Agents in the Field of HCC
Author(s):
Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).
Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).
The field has recently seen promising data and an FDA approval of regorafenib (Stivarga) in the second-line setting of HCC treatment, Finn explains. At the 2017 International Liver Cancer Association Annual Conference, updated overall survival (OS) data on the phase III RESORCE trial, which compared regorafenib with placebo, will also be presented.
Additionally, there is an emerging role for immunotherapy in this field, Finn adds. Nivolumab (Opdivo) is also being explored in an ongoing phase III trial, which has previously shown encouraging activity. FGFR4 inhibitors are also demonstrating early promise; early data are beginning to show clinical activity in a biomarker-selected population of patients with liver cancer.
Brought to you in part by Eisai
